“The mission of Covaxx is to defeat Covid-19 and ultimately democratise health worldwide — Maersk will help fulfil this mission”
Maersk has inked a global logistics partnership with U.S. company COVAXX for delivery of COVAXX’s coronavirus vaccine.
COVAXX is currently conducting Phase 1 clinical trials of its vaccine in Taiwan and has an agreement with the University of Nebraska Medical Center to conduct Phase 2 trials in the United States, upon regulatory approval. COVAXX is developing UB-612, a multitope synthetic peptide-based vaccine to fight COVID-19.
The Hauppauge, New York-based company, a subsidiary of United Biomedical, said it already has “advanced precommitments” from around the world for more than 100 million doses of the vaccine.
COVAXX is planning to manufacture 100m doses of its vaccine during early 2021, and a billion doses by the end of 2021.
The world’s largest container carrier, Denmark-headquartered Maersk has more than 80,000 employees operating in 130 countries.
Maersk will oversee all logistics activities to ensure efficient transportation to developing countries.
“Efficient and safe delivery of COVID-19 vaccines around the world is the most urgent logistics challenge we face today. A.P. Møller – Maersk is committed to working closely with COVAXX to ensure smooth end-to-end global delivery of this vaccine as soon as it becomes available. Our specialized logistics expertise and the global infrastructure of Maersk make this a perfect match” said Rob Townley, Maersk’s head of special project logistics.
Logistics is reaching further and further into every part of our daily lives, how will you be part of the industry?